Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.

Authors

• Bing Han
• Yan-Yan Zhang
• Ze-Qing Ye
• Yun Xiao
• Javad Rasouli
• Wen-Cheng Wu
• Su-Min Ye
• Xin-Yue Guo
• Lin Zhu
• Abdolmohamad Rostami
• Li-Bin Wang
• Yuan Zhang
• Xing Li

Publication/Presentation Date

6-1-2021

Abstract

Montelukast is a leukotriene receptor antagonist that is known to prevent allergic rhinitis and asthma. Blocking the Cysteinyl leukotriene receptor (CysLTR1), one of the primary receptors of leukotrienes, has been demonstrated to be efficacious in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), through disrupting chemotaxis of infiltrating T cells. However, the role of CysLTR1 in the pathogenesis of MS is not well understood. Here, we show that MS patients had higher expression of CysLTR1 in the circulation and central nervous system (CNS). The majority of CD4

Volume

163

Issue

2

First Page

185

Last Page

200

ISSN

1365-2567

Published In/Presented At

Han, B., Zhang, Y. Y., Ye, Z. Q., Xiao, Y., Rasouli, J., Wu, W. C., Ye, S. M., Guo, X. Y., Zhu, L., Rostami, A., Wang, L. B., Zhang, Y., & Li, X. (2021). Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model. Immunology, 163(2), 185–200. https://doi.org/10.1111/imm.13308

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

33480040

Department(s)

Administration and Leadership

Document Type

Article